| 000 | 01724 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516100003.0 | ||
| 264 | 0 | _c20120920 | |
| 008 | 201209s 0 0 eng d | ||
| 022 | _a1203-4754 | ||
| 024 | 7 |
_a10.1177/120347541201600305 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPapp, Kim A | |
| 245 | 0 | 0 |
_aBiologic therapy in psoriasis: perspectives on associated risks and patient management. _h[electronic resource] |
| 260 |
_bJournal of cutaneous medicine and surgery _c |
||
| 300 |
_a153-68 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 | _aAlefacept |
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aBiological Products _xadverse effects |
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 |
_aDermatologic Agents _xadverse effects |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadverse effects |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadverse effects |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUstekinumab |
| 700 | 1 | _aDekoven, Joel | |
| 700 | 1 | _aParsons, Laurie | |
| 700 | 1 | _aPirzada, Syed | |
| 700 | 1 | _aRobern, Michael | |
| 700 | 1 | _aRobertson, Lynne | |
| 700 | 1 | _aTan, Jerry K L | |
| 773 | 0 |
_tJournal of cutaneous medicine and surgery _gvol. 16 _gno. 3 _gp. 153-68 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/120347541201600305 _zAvailable from publisher's website |
| 999 |
_c21878035 _d21878035 |
||